New research shows that new and experimental treatment options are becoming more widely available for the billions of males living with prostate cancer all over the globe.
The FDA authorized a brand-new prostate cancer treatment on August 5th, 2022.
Darolutamide combined with Docetaxel is the new treatment name for patients with hormone-sensitive metastatic prostate cancer (mHSPC).
It can also be utilized with the chemotherapy drug docetaxel to treat metastatic castration-sensitive prostate cancer.
Here’s everything you need to learn about the new prostate cancer treatment in 2022.
The Problem With Prostate Cancer Treatment Today
Since prostate cancer is the most typical cancer among males, people must be aware of all potential treatment options.
Treatment for prostate cancer can be pretty complex, especially given that prostate cancer can occur in many different stages.
This indicates that treatment alternatives differ from person to person, meaning there is no one-size-fits-all approach to treatment.
Many types of treatment alternatives are available for men diagnosed with prostate cancer.
These include the following:
- Radiation therapy
- Hormone therapy
- Watchful waiting
One of the essential things for men to remember about prostate cancer treatment is that there is no one-size-fits-all approach to treatment.
This means that treatment options vary from person to person, meaning there is no one-size-fits-all approach to treatment.
More about Darolutamide
Darolutamide is a new drug that is currently in clinical trials. This drug works by stopping androgen receptors in the prostate from absorbing testosterone, one of the leading causes of prostate cancer.
Androgen receptors are located on the surface of cells in the prostate, and they are responsible for taking in blood-borne hormones like testosterone.
Darolutamide works by blocking these receptors from taking in testosterone.
This drug is currently being studied as a potential treatment option for men diagnosed with metastatic prostate cancer.
This signifies that cancer has extended from the prostate to other body parts.
Darolutamide is also being studied as a potential treatment for men diagnosed with non-metastatic prostate cancer that has progressed despite hormone therapy.
Internationally, the phase 3 ARASENS trial was conducted randomly on 1305 patients with newly discovered metastatic hormone-sensitive prostate cancer (average age: 67 years).
86% of the patients were recently diagnosed with prostate cancer extending to the bones or other body parts.
ADT was administered to all patients 12 weeks before the trial, and six cycles of Docetaxel were administered beginning six weeks after the test.
Docetaxel, standard ADT, and Darolutamide 600 mg twice daily were given to 651 patients vs. placebo, Docetaxel and standard ADT were given to 654 patients.
The outcomes of this study were shown at the Genitourinary Cancers Symposium on February 17th, 2022, in San Francisco, California, and issued in the New England Journal of Medicine.
Outcomes of the Study
Compared to patients ministered with ADT and Docetaxel alone, patients treated with Darolutamide have a 32% lower follow-up mortality rate.
Approximately 62.7% of patients who took Darolutamide were alive after four years, compared to 50.4% of patients who got a placebo.
Most patients in the placebo group (75%) received other widely used treatments during the follow-up, such as abiraterone and enzalutamide. In contrast, the Darolutamide-treated group lived longer.
Additionally, these patients had a shorter time of castration resistance (even after the hormone treatment, the PSA grows and the condition aggravates).
Reduce the period of pain progression and Symptomatic skeletal-associated events (i.e., bone fractures, requiring radiation to the bones) and the period following cancer therapy.
Significantly, the intensification of triplet therapy was associated with these improved outcomes while only slightly increasing adverse events.
It does not result in decreased bone density, gynecomastia, or dysfunctional sex.
Shortly, it might take over as the preferred method of treating prostate cancer.
Key points of this latest prostate cancer treatment
– This treatment may help slow down cancer progression, saving men from undergoing additional treatment.
– This treatment appears well-tolerated by patients, meaning they experience few side effects.
– This treatment may be an option for men who have failed hormone therapy.
– This drug could potentially be used in combination with other drugs in the future.
– This drug is expected to be available in clinical trials by 2022, meaning it may not be available for everyone.
– This drug is expected to be administered at a medical facility.
Side effects of the latest prostate cancer treatment
– This treatment may reduce men’s sex drive.
– This drug may cause men to experience urinary problems.
– This treatment may lead to fatigue and joint pain.
This new treatment alternative has the potential to be one of the most effective treatments for prostate cancer in 2022.
This new treatment is expected to be well-tolerated by patients, which means that it has few side effects.
This treatment also appears to be effective at slowing down the progression of prostate cancer.
This latest treatment alternative could be an option for men with a diagnosis of non-metastatic prostate cancer that has progressed despite hormone therapy.
This treatment may also be an option for men who have received a metastatic prostate cancer diagnosis and have failed other treatments.
This treatment may also be an option for men who have received a diagnosis of incurable prostate cancer.
The article originally published on Science Atom.